261 related articles for article (PubMed ID: 18685359)
21. [Renal cell carcinoma management and therapies in 2010].
Albouy B; Gross Goupil M; Escudier B; Massard C
Bull Cancer; 2010; 97():17-28. PubMed ID: 20418201
[TBL] [Abstract][Full Text] [Related]
22. Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence.
Hutson TE
Oncologist; 2011; 16 Suppl 2(Suppl 2):14-22. PubMed ID: 21346036
[TBL] [Abstract][Full Text] [Related]
23. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.
Choueiri TK; Vaziri SA; Jaeger E; Elson P; Wood L; Bhalla IP; Small EJ; Weinberg V; Sein N; Simko J; Golshayan AR; Sercia L; Zhou M; Waldman FM; Rini BI; Bukowski RM; Ganapathi R
J Urol; 2008 Sep; 180(3):860-5; discussion 865-6. PubMed ID: 18635227
[TBL] [Abstract][Full Text] [Related]
24. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
Miller K; Bergmann L; Jäger E; Jakse G; Wirth M; Keilholz U;
Aktuelle Urol; 2009 Jan; 40(1):27-30. PubMed ID: 19177318
[TBL] [Abstract][Full Text] [Related]
25. [Angiogenesis targeting in renal carcinomas].
Pouessel D; Culine S
Bull Cancer; 2007; 94(7 Suppl):F223-6. PubMed ID: 17965000
[TBL] [Abstract][Full Text] [Related]
26. Metastatic renal cell cancer treatments: an indirect comparison meta-analysis.
Mills EJ; Rachlis B; O'Regan C; Thabane L; Perri D
BMC Cancer; 2009 Jan; 9():34. PubMed ID: 19173737
[TBL] [Abstract][Full Text] [Related]
27. [Advanced renal carcinomas with special situations. How to treat them?].
Pouessel D; Patard JJ; Culine S
Bull Cancer; 2010; 97():83-90. PubMed ID: 20418207
[TBL] [Abstract][Full Text] [Related]
28. [Angiogenesis and renal cell carcinoma].
Billemont B; Méric JB; Izzedine H; Taillade L; Sultan-Amar V; Rixe O
Bull Cancer; 2007 Jul; 94 Spec No():S232-40. PubMed ID: 17846009
[TBL] [Abstract][Full Text] [Related]
29. Progress in the management of advanced renal cell carcinoma (RCC).
Tong TQ; Rohde D; Peter S
Aktuelle Urol; 2010 Jan; 41 Suppl 1():S57-60. PubMed ID: 20094957
[TBL] [Abstract][Full Text] [Related]
30. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma.
Krajewski KM; Guo M; Van den Abbeele AD; Yap J; Ramaiya N; Jagannathan J; Heng DY; Atkins MB; McDermott DF; Schutz FA; Pedrosa I; Choueiri TK
Eur Urol; 2011 May; 59(5):856-62. PubMed ID: 21306819
[TBL] [Abstract][Full Text] [Related]
31. Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma.
Benedict A; Figlin RA; Sandström P; Harmenberg U; Ullén A; Charbonneau C; Sandin R; Remák E; Hariharan S; Négrier S
BJU Int; 2011 Sep; 108(5):665-72. PubMed ID: 21265994
[TBL] [Abstract][Full Text] [Related]
32. Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development.
Rini BI; Sosman JA; Motzer RJ
BJU Int; 2005 Aug; 96(3):286-90. PubMed ID: 16042715
[No Abstract] [Full Text] [Related]
33. Sunitinib, sorafenib, temsirolimus or bevacizumab in the treatment of metastatic renal cell carcinoma: a review of health economic evaluations.
Norum J; Nieder C; Kondo M
J Chemother; 2010 Apr; 22(2):75-82. PubMed ID: 20435564
[TBL] [Abstract][Full Text] [Related]
34. [The role of angiogenesis in renal carcinoma].
Bussolati B; Satolli MA; Camussi G
G Ital Nefrol; 2008; 25(3):297-305. PubMed ID: 18473301
[TBL] [Abstract][Full Text] [Related]
35. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
Golshayan AR; George S; Heng DY; Elson P; Wood LS; Mekhail TM; Garcia JA; Aydin H; Zhou M; Bukowski RM; Rini BI
J Clin Oncol; 2009 Jan; 27(2):235-41. PubMed ID: 19064974
[TBL] [Abstract][Full Text] [Related]
36. Treatment options for metastatic renal cell carcinoma: a review.
Athar U; Gentile TC
Can J Urol; 2008 Apr; 15(2):3954-66. PubMed ID: 18405442
[TBL] [Abstract][Full Text] [Related]
37. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.
Tamaskar I; Garcia JA; Elson P; Wood L; Mekhail T; Dreicer R; Rini BI; Bukowski RM
J Urol; 2008 Jan; 179(1):81-6; discussion 86. PubMed ID: 17997441
[TBL] [Abstract][Full Text] [Related]
38. [Impact of immunotherapy in metastatic kidney cancer in Germany after introduction of new target therapy--results of a telephone survey of the German Society of Immuno- and Targeted Therapy (DGFIT)].
Siebels M; Staehler M; Hegele A; Varga Z; Oberneder R; Doehn C; Heinzer H;
Aktuelle Urol; 2010 Mar; 41(2):122-30. PubMed ID: 19937556
[TBL] [Abstract][Full Text] [Related]
39. Molecular biology of renal cell carcinoma.
Mellado B; Gascón P
Clin Transl Oncol; 2006 Oct; 8(10):706-10. PubMed ID: 17074668
[TBL] [Abstract][Full Text] [Related]
40. [Renal cell carcinoma].
Obara W; Fujioka T
Gan To Kagaku Ryoho; 2008 Sep; 35(9):1482-7. PubMed ID: 18799901
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
